$1.04
-0.04 (-3.70%)
Open$1.11
Previous Close$1.08
Day High$1.13
Day Low$1.03
52W High$13.48
52W Low$0.89
Volume—
Avg Volume534.0K
Market Cap14.78M
P/E Ratio—
EPS$-3.58
SectorBiotechnology
Analyst Ratings
Strong Buy
5 analysts
Price Target
+4,267.3% upside
Current
$1.04
$1.04
Target
$45.42
$45.42
$30.66
$45.42 avg
$56.99
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 18.47M | 17.78M | 17.86M |
| Net Income | 823.9K | 633.2K | 616.7K |
| Profit Margin | 4.5% | 3.6% | 3.5% |
| EBITDA | 1.32M | 1.18M | 1.27M |
| Free Cash Flow | 745.4K | 469.0K | 453.6K |
| Rev Growth | +3.4% | -9.1% | -0.5% |
| Debt/Equity | 0.78 | 0.66 | 0.81 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |